No Data
Merck & Co spends $9.2 billion to acquire growth story as biopharmaceutical company Cidara's stock price soars.
①Merck & Co announced a $9.2 billion acquisition of Cidara Therapeutics to address the sales gap expected from the expiration of Keytruda's patent; ②Cidara’s CD388 drug is a long-acting antiviral medication designed to prevent both influenza A and B. The drug is currently under evaluation in Phase III clinical trials.
RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck
Market Movers: Topgolf, StubHub, Applied Materials, Cidara Therapeutics...
Top Midday Gainers
Raising the Bar: Can Higher Drug Spending in the UK Deliver for Pharma and Patients?
Top Stock Movers Now: StubHub, DoorDash, Netflix, and More